Horses with equine infectious anemia virus (EIAV) have episodes of viremia and disease; however, most eventually become inapparent carriers. A possible mechanism of control is cytotoxic T lymphocytes (CTL). To evaluate CTL in inapparent carriers with low viral loads, peripheral blood mononuclear cells (PBMC) were stimulated in vitro with autologous EIAVinfected PBMC and human IL-2 to detect memory CTL (CTLm). In initial studies, three carriers had CTLm and one of these had low-level effector CTL (CTLe). The CTLm were restricted by equine lymphocyte alloantigen-A (ELA-A) locus encoded MHC class I molecules on autologous equine kidney (EK) target cells. In addition, EK cells did not express MHC class II molecules. The CTLm frequency in PBMC from five inapparent carriers infected for 22 to 50 months was determined by limiting dilution analysis. PBMC were diluted, stimulated, and tested on EK cell targets infected with EIAV and recombinant vaccinia viruses expressing EIAV Env or Gag/Pr proteins. All five carriers had CTLm to EIAV-infected targets, while four had CTLm to targets expressing Env and four had CTLm to targets expressing Gag/Pr proteins. The CTLm frequency range was 60 to 468 per 10 6 PBMC to EIAV-infected targets, 4 to 286 to Env-expressing targets, and 25 to 190 to Gag/Prexpressing targets. These results should facilitate the identification of epitopes recognized by predominant CTLm from horses controlling a lentivirus infection. ᭧ 1997 Academic Press of EIAV to noninfected horses (Coggins et al., 1972; 
.
The mechanisms carrier horses use to control EIAV Equine infectious anemia virus (EIAV) causes disease are not known. Infected horses control the initial plasma in horses with some distinctive features when compared viremia by specific immune responses since young with other lentiviral infections of humans and animals.
horses with severe combined immunodeficiency fail to There is an episode of plasma viremia with associated terminate initial viremia, while immunocompetent young fever, thrombocytopenia, and anemia within 1 to 4 weeks horses terminate the initial viremia (Perryman et al., after infection which lasts several days (Kono, 1969; Cog-1988) . Whether antibody or other lymphocyte responses gins et al., 1972) . Most horses infected with either wildare involved is unknown because young horses with setype strains (Kono, 1969) or strains derived from the tisvere combined immunodeficiency lack functional T and B sue culture-adapted prototype strain (Orrego et al., 1982;  lymphocytes (McGuire et al., 1975) . Antibodies mediating O' Rourke et al., 1988) terminate the initial disease epiantibody-dependent cellular cytotoxicity (ADCC) do not sode, although some horses infected with wild-type appear to be involved in virus control because these strains may die during the initial disease. Surviving antibodies cannot be demonstrated in sera from infected horses usually have episodes of viremia and clinical dishorses (Fujimiya et al., 1979; Tschetter et al., 1997) . Neuease interspersed with quiescent periods of one to sevtralizing antibodies are detected following infection with eral weeks during the first few months after infection EIAV (Kono, 1969) and the specificity of the neutralizing (Kono, 1969; Orrego et al., 1982; .
antibody response broadens during persistent infection Then, the disease episodes become less frequent until (O'Rourke et al., 1989; Rwambo et al., 1990) . The delayed the horses are inapparent carriers with low virus loads appearance of type-specific neutralizing antibodies after (Kono, 1969; Issel et al., 1982; Coggins, 1984; Langemeier the termination of viremia by that virus type (Carpenter et al., 1996) . Carriers live for years and can be detected O'Rourke et al., 1989; Rwambo et al., 1990 ) by antibodies to EIAV proteins and by blood transmission and the antigenic variation of epitopes recognized by neutralizing antibody (Kono et al., 1973b; Montelaro et al., 1984) may limit the effectiveness of neutralizing anti- antibody is indicated by passive transfer of plasma containing neutralizing antibodies from EIAV-infected to Frequency of CTLm in PBMC from EIAV Carrier Horses noninfected horses (Rushlow et al., 1990) . conversion and in one case delayed clinical disease (Rushlow et al., 1990) . (Kono et al., 1973a) and vaccinated horses (Issel et al., 1992) resisting challenge in the absence of detectable neutralizing antibody. Active immune responses are ima The equine lymphocyte alloantigen (ELA-A) haplotypes were identiplicated in EIAV control by carrier horses since either fied by microcytotoxicity assays using described serologic reagents (Bailey, 1980 (Bailey, , 1983 . corticosteroids or cyclophosphamide causes plasma viremia within 1 to 2 weeks after treatment (Kono et al., 1976; Tumas et al., 1994) . The virus in plasma following nies) were used in these experiments. EIAV wsu5 is a cell treatment is a neutralizing antibody escape-variant apculture-adapted strain isolated after three sequential pearing while neutralizing antibody to the variant used for passages of the prototype strain (Malmquist et al., infection is still detectable (Kono et al., 1976) . Therefore, 1973) in horses and the predominant virus type seneutralizing antibody in plasma probably controls viremia lected by three limiting dilutions on EK cell cultures by recognized EIAV variants. New variants, and virus . EIAV wsu5 causes viremia and replication to generate new variants, may be controlled clinical disease in young horses ) by T lymphocyte responses including cytotoxic T lymphoand ponies McGuire et al., 1994b) . cytes (CTL).
Infection of H-507, H-521, and H-525 and the method of Since our long-term goal is to clarify the mechanisms obtaining autologous EK cells from kidney biopsies for that inapparent carrier horses use to control EIAV replica-CTL target cells have been described (McGuire et al., tion, we are investigating the hypothesis that MHC class 1994b). Similar procedures were used to obtain EK cells I-restricted virus-specific CD8 / CTL are involved. To this from 18 noninfected horses and to infect 2 of these, Hend, CTL meeting these criteria were previously demon-529 and H-532, with 10 9 50% tissue culture infective strated in peripheral blood mononuclear cells (PBMC) doses (TCID 50 ) of EIAV wsu5 . Except for H-507 (McGuire et coincident with the initial viremic episode in infected al., 1994b), the other 4 infected horses had at least one horses (McGuire et al., 1994b) . These were effector CTL episode of fever, viremia, and thrombocytopenia. The (CTLe) not requiring in vitro stimulation and were present mean platelet count for 16 noninfected horses (mixed for at least 3 months after infection. Thereafter, CTLe breed ponies) in this study was 214,855/ml and thrombolevels in PBMC declined (unpublished observation). Recytopenia was defined as õ100,800/ml which was 2 SD cently, EIAV-specific memory CTL (CTLm) were demonbelow the mean. Equine lymphocyte alloantigen-A (ELAstrated in PBMC from inapparent carriers using as target A) locus encoded MHC class I proteins on lymphocytes cells pokeweed mitogen-stimulated PBMC infected with (Table 1) were identified by microcytotoxicity assays usrecombinant vaccinia viruses expressing EIAV proteins ing described serologic reagents (Bailey, 1980 (Bailey, , 1983 . (Hammond et al., 1997) . One way to further evaluate the The ELA-A locus is the only well-defined class I locus in role of CTL in controlling viral load is to induce CTL in the horse (Lazary et al., 1988) . horses by immunization and to evaluate the effects of EIAV challenge. Since epitopes recognized by predominant CTLm from inapparent carriers may induce the req-Assays for CTLe and CTLm uisite response for evaluation, experiments were done to demonstrate CTLm in carriers to equine kidney (EK)
To measure CTLe, freshly isolated, nonstimulated PBMC (Wyatt et al., 1988) were evaluated using a 51 Cr cell targets expressing EIAV proteins, to further indicate that the CTLm were MHC class I-restricted, and to do release assay with a 17-hr incubation period (McGuire et al., 1994b) . The formula, % specific lysis Å [(E 0 S)/ limiting dilution analysis to determine CTLm frequency to EIAV-infected target cells and to target cells expressing (M 0 S)] 1 100 (Siliciano et al., 1985) was used, where E is the mean of six test wells, S is the mean spontaneous either Env or Gag/Pr proteins.
release from six target cell wells without effector cells, MATERIALS AND METHODS and M is the mean maximal release from six target cell EIAV-infected and control horses wells with 2% Triton X-100 in distilled water. The standard error (SE) of percentage specific lysis was calculated Five horses (mixed breed ponies) infected with EIAV wsu5 and 16 noninfected horses (mixed breed po-using a formula that accounts for the variability of E, S, and M (Siliciano et al., 1985) . Only assays with a sponta-6 days. Cells from each of the 24 wells were resuspended neous lysis of õ30% were used. and transferred to a well of EK target cells labeled with To detect CTLm, 10 6 PBMC were stimulated in 24-well 51 Cr (McGuire et al., 1994b) . The plates were incubated plates with each well containing 1 ml of RPMI 1640 with at 37Њ for 17 hr and centrifuged for 5 min at 200 g, and 10% fetal calf serum, 5 1 10 05 M 2-mercaptoethanol, and 0.1 ml of supernatant was removed to determine 51 Cr 20 mM HEPES plus 10 6 irradiated stimulator PBMC which release. contained EIAV wsu5 -infected monocytes. These stimulator cells were prepared by exposing 10 8 autologous PBMC Analysis of limiting dilution assay data to 3000 rad of gamma irradiation, mixing with 2 ml containing 10 6 TCID 50 /ml EIAV wsu5 , and incubating at 37Њ for Each of the 24 wells of the limiting dilution assay was 1 hr. After 7 days of stimulation, viable lymphocytes were scored as positive or negative based on whether the isolated using Histopaque and restimulated in a 24-well 51 Cr release exceeded a specific lysis threshold. The plate with each well containing 4 1 10 5 isolated lymphothreshold was calculated as the mean spontaneous recytes and 10 6 stimulator cells in 1 ml of the above melease / 10% of the specific release (Carmichael et al., dium plus 20 units/ml recombinant human IL-2 (Gibco 1993) . For each target cell type, the mean spontaneous BRL, Grand Island, NY), which stimulates equine lymphorelease from 12 target cell wells without effector cells cytes (Magnuson et al., 1987) . Restimulation was done and the mean maximal release from 12 target cell wells every 3-4 days and lymphocytes stimulated for 14 to 20 with 2% Triton X-100 in distilled water were determined, days were evaluated for CTL activity using the same and the specific release was calculated as the mean assay procedure and calculations described for CTLe. maximal release minus the mean spontaneous release. The wells without CTLm and those with at least one CTLm frequency in PBMC from carrier horses to EIAV-specific CTLm had bimodal distributions of 51 Cr re-EIAV-infected targets lease that were consistently differentiated using the described threshold (Carmichael et al., 1993) . The limiting Quantitative estimates of CTLm were derived by limdilution data were analyzed by calculating the frequency iting dilution analysis of PBMC that were first diluted and of CTL and a 95% confidence limit using the maximum then stimulated (Carmichael et al., 1993) . Dilutions of likelihood method and testing the goodness of fit of the PBMC were made in DMEM with 15% fetal calf serum data with the Poisson model by calculating x 2 (Fazekas and 15% calf serum (DMEM / ) so that 0.1 ml containing 10,000, 5000, 2500, and 1250 PBMC could be added to De St Groth, 1982) . wells of a 96-well (round-bottom) plate. Three sets of 24 wells for each dilution were stimulated before assaying CTLm killing and CTLm frequency using cell targets for CTL activity on three different target cells including expressing EIAV Env and Gag/Pr proteins EIAV wsu5 -infected autologous and ELA-A mismatched EK cells and noninfected autologous EK cells. Stimulation Before using EK cell targets infected with recombinant of PBMC was done in each well by adding EIAV wsu5vaccinia viruses expressing Env or Gag/Pr proteins in infected monocytes. The monocytes were isolated using limiting dilution assays for CTLm, these target cells were gelatin and autologous plasma-coated flasks (Freundlich evaluated with stimulated PBMC in CTL assays. One and Avdalovic, 1983; Maury, 1994) . Briefly, 2 1 10 7 PBMC recombinant vaccinia virus was used, VGag/Pr), which irradiated with 3000 rad in 15 ml of RPMI 1640 with expresses the EIAV wsu5 55-kDa Gag precursor and an 20% calf serum were added to 75-cm 2 coated flasks and 82-kDa Gag/Pol fusion protein including protease (PR), incubated for 1 hr at 37Њ, and non-adherent cells were which are processed into subviral particles containing removed by washing three times with HBSS warmed to p26 (McGuire et al., 1994a) . Another recombinant virus 37Њ. Adherent monocytes were infected by adding 6 ml/ was VEnv2, which expresses the EIAV wsu5 Env precursor flask containing 10 5.5 TCID 50 /ml EIAV wsu5 , incubating at that is cleaved by cellular proteases into SU and TM 37Њ for 1 hr, and then washing once with RPMI with 20% proteins (McGuire et al., 1994b) . A control recombinant calf serum. Infected monocytes were removed by adding virus, VSC11, which expresses beta-galactosidase, was 5 ml/flask HBSS with 10 mM EDTA plus 5 ml/flask RPMI also used, but EIAV proteins were not used (McGuire et with 20% calf serum and incubating at 37Њ for 15 min. al., 1994b) . Finally, recombinant vaccinia virus-infected Following centrifugation for 10 min at 200 g and washing EK target cells expressing EIAV proteins were used to once with DMEM / , 10 5 infected monocytes in 0.1 ml were determine the frequency of CTLm in PBMC from five added to each well of effector cells and incubated for 6 carrier horses infected for 22 to 50 months. The PBMC days in a humidity chamber at 37Њ with 5% CO 2 . Then, were diluted from 32,000 to 4000/well and stimulated, 0.1 ml of medium was removed from each well, replaced and limiting dilution analysis of CTL activity was done with 0.1 ml of DMEM / containing 40 units/ml of recombinant human IL-2 (Gibco BRL), and incubated for another as described in the two preceding paragraphs.
RESULTS
ure to kill EIAV-infected target cells from other horses (mismatched) and elimination of CTL activity by removal CTLe and CTLm in PBMC from EIAV-infected horses of CD8 / T lymphocytes with a MAb to equine CD8 Prior to assays to measure CTL in PBMC, the five (McGuire et al., 1994b) . The role of MHC class I-re-EIAV-infected horses were evaluated for 5 weeks by takstricted killing of EIAV-infected EK target cells was impliing daily body temperatures and determining platelet cated in the current paper by demonstrating that these counts, packed cell volumes, and plasma viremia three cells expressed MHC class I, but not MHC class II moletimes per week. During this period, three horses (H-507, cules. Three MAbs (Davis et al., 1987; Kydd et al., 1994) H-521, and H-525, infected for 34, 24, and 22 months, reacting with monomorphic determinants of equine MHC respectively) lacked plasma viremia detectable by assay class I (H58A, PT85A, and B5C) stained 97.4 to 98.4% of on EK cell cultures . They also the EK cells by fluorescent flow cytometry while three lacked fever, anemia, and thrombocytopenia and were MAbs reacting with monomorphic determinants of considered carriers. The two other horses (H-529 and Hequine MHC class II (H34A, TH14B, and TH81A) bound 532), which were infected for only 6 months, were not 2.4 to 4.6% of EK cells. Isotype control MAbs bound 1.4 considered carriers as both had low-level, but detectable, and 2.5% of EK cells. viremia (10 1.3 and 10 1.5 TCID 50% /ml, respectively). These Killing of infected EK target cells was further confirmed two horses had no fever, thrombocytopenia, or anemia to be MHC class-I restricted by evaluating killing of target except for H-529, which had thrombocytopenia on one cells from horses of known ELA-A types by stimulated occasion.
PBMC from H-532. These PBMC caused significant lysis To measure CTLe, freshly isolated, nonstimulated of EIAV wsu5 -infected autologous EK target cells and of PBMC were used in the 51 Cr release assay. PBMC from infected EK target cells from horses with one matched carriers H-507 and H-521 did not have CTLe as neither ELA-A haplotype, but not of infected target cells from caused significant lysis of autologous EIAV wsu5 -infected horses with a mismatch of both ELA-A haplotypes (Fig. EK target at 10:1 and 50:1 effector to target (E:T) cell 2). The percentage specific lysis of mismatched, but inratios (Fig. 1) . However, PBMC from carrier H-525 at a fected, target cells was greater than uninfected target 50:1 E:T cell ratio had low-level CTLe causing significant cells when A7/w11 and A1/w11 targets were used; howlysis (12.1%) of infected EK targets (Fig. 1) . The percentever, the percentage lysis did not exceed that occurring age specific lysis of autologous infected EK target cells with uninfected autologous cells and was not considered was considered significant when it exceeded the specific significant (see the definition in the legend to Fig. 2) . The lysis of both autologous noninfected EK cells and ELAhighest level of EIAV-specific killing occurred when the A-mismatched, EIAV wsu5 -infected EK cell targets by three infected target cells were autologous and killing of intimes the standard error. PBMC from H-529, one of the fected target cells with one matched ELA-A haplotype two horses with low-level viremia, caused very low, but was about 50% less (Fig. 2 ). significant, lysis (8.6% at a 50:1 E:T cell ratio) of infected targets (Fig. 1) . PBMC from H-532, the other horse with CTLm frequency in carrier horse PBMC to EIAVlow-level viremia, had 13.7 and 22.0% lysis at E:T ratios infected targets of 10:1 and 50:1, respectively (Fig. 1) .
CTLm were measured following in vitro stimulation of The number of CTLm to EIAV-infected targets was de-PBMC, and PBMC from carriers (H-507, 521, and 525) termined by limiting dilution analysis of PBMC from the caused significant lysis of autologous EIAV wsu5 -infected same five infected horses described above, but it was EK target cells at E:T cell ratios of 5:1 and 25:1 with lysis done 16 months later. The horses were now infected for at the 25:1 cell ratio ranging from 24.0 to 34.9% (Fig.  22 to 50 months and all were considered carriers as 1). Stimulated PBMC from the two horses with low-level clinical disease (anemia and thrombocytopenia) was not viremia also caused significant lysis of autologous indetected for 5 weeks and viremia was not detected by fected targets at both E:T cell ratios with 25.8% for H-529 assay on EK cell cultures during the subsequent 4 weeks. and 54.8% for H-532 at the 25:1 E:T cell ratio (Fig. 1) .
The frequency of CTLm in the diluted and stimulated Expression of MHC class I on EK target cells and PBMC from these carrier horses to EIAV wsu5 -infected aurestriction of CTL killing by ELA-A tologous EK target cells ranged between 60 and 468 per 10 6 PBMC (Table 1) with a mean frequency of 293 per Previous evidence that EIAV-specific CTLe from infected horses were MHC class I-restricted included fail-10 6 PBMC. There was no lysis in wells containing either CTLm killing of target cells expressing Env or Gag/Pr proteins Prior to using EK cell targets infected with recombinant vaccinia viruses expressing EIAV proteins in limiting dilution assays, killing of these targets by stimulated PBMC from H-532 was evaluated. These PBMC caused significant lysis of autologous EK target cells infected with recombinant vaccinia viruses expressing either Env or Gag/Pr proteins when compared to controls of noninfected autologous EK target cells and autologous EK target cells infected with VSC11 (Fig. 3) . The specific lysis at an E:T cell ratio of 10:1 was similar with target cells expressing Gag/Pr or Env proteins, but both targets were lysed less than EIAV wsu5 -infected target cells (Fig. 3) . The relative efficiency of EIAV protein epitope expression by MHC class I molecules on EK target cells infected with either EIAV or recombinant vaccinia viruses expressing EIAV proteins is unknown. The demonstration of CTLm to both Env and Gag/Pr protein epitopes indicated that cell targets expressing these epitopes were suitable for The number of CTLm recognizing either target cells columns are SEs. Asterisks above the columns indicate significant expressing Env proteins or Gag/Pr proteins was deterspecific lysis that was three SEs greater than that occurring with either the autologous noninfected EK cells or the ELA-A-mismatched, EIAV wsu5 -infected EK cell targets. noninfected autologous or EIAV wsu5 -infected, ELA-A-mismatched EK target cells, indicating that õ5 CTL per 10 6 PBMC recognized these targets. The õ5 CTL per 10 6 PBMC is based on negative results in 24 wells containing the maximum number of 10,000 PBMC tested/well. As a control, the CTLm frequency in PBMC from three non-EIAV-infected horses was evaluated and PBMC from two of these noninfected horses had no detectable CTL to EIAV wsu5 -infected or control EK cell targets. However, PBMC from a third noninfected horse (H-504) had 155 and 178 CTLm per 10 6 PBMC in two experiments with autologous EIAV-infected EK cell targets. There were 31 and 5 CTL per 10 6 PBMC with autologous noninfected EK cell targets and õ5 CTL per 10 6 with EIAV-infected ELA-A mismatched EK cell targets. In a separate limiting dilution assay run as described in a subsequent section, stimulated H-504 PBMC did not lyse EK cells expressing recombinant Env or Gag/Pr proteins. In addition, nonstim- SEs. Asterisks above the columns indicate significant specific lysis From this result, it was concluded that the killing of EIAVthat was three SEs greater than that occurring with autologous nonininfected target cells by one uninfected horse, H-504, was fected EK target cells, ELA-A-mismatched EIAV wsu5 -infected EK target cells, and VSC11-infected target cells.
uncommon and probably of little significance. with CTLm from two horses with low-level viremia. There was low-level, but significant, specific lysis by CTLe in Frequency of CTLm per 10 6 PBMC (95% Confidence Interval) unstimulated PBMC from one of three EIAV carriers. This Specific for EIAV Env and Gag/Pr Proteins latter observation was similar to the detection of in vivo-EK target cells infected with recombinant activated CTL in a person infected with HIV-1 for 15 years vaccinia viruses and with very low viral load (Harrer et al., 1996) target cells were easily demonstrated in the three carrier horses evaluated. Moreover, CTLm from a carrier horse mined by limiting dilution analysis of PBMC from the five recognized epitopes from EIAV Env and Gag/Pr proteins carrier horses. Four of five carriers had CTLm which as previously described for CTLe from recently infected killed autologous EK cells expressing Env proteins and horses (McGuire et al., 1994b; Hammond et al., 1997) and the range was 4 to 286 per 10 6 PBMC. A fifth carrier had for CTLm from carriers (Hammond et al., 1997) , allowing õ2 per 10 6 PBMC ( Table 2 ). The õ2 CTL per 10 6 PBMC target cells expressing these proteins to be used in limis based on negative results in 24 wells containing the iting dilution analysis. maximum number of 32,000 PBMC tested/well. The
The CTLm lysis of EK target cells infected with EIAV CTLm per 10 6 PBMC from four of the five carriers killing or expressing EIAV proteins was indicated to be MHC autologous EK cells expressing Gag/Pr proteins was 25 class I-restricted by demonstrating that EK target cells to 190, while the fifth carrier had õ2 ( Table 2 ). The three expressed MHC class I molecules, but not class II molehorses with the highest number of CTLm to EIAV-infected cules. The CTL-specific lysis of EK target cells was as cells had the highest number of CTLm to both Env-and high as 54.8% (Fig. 1) and occurred in the absence of Gag/Pr-expressing target cells (Tables 1 and 2 ). The MHC class II molecules. This indication was further suphorse with the lowest number of CTLm to EIAV-infected ported by demonstrating lysis of autologous EIAV-intarget cells (H-525) had barely detectable CTLm to Env fected target cells and of infected target cells from horses and Gag/Pr proteins. Four carriers had õ2 CTLm per 10 6 with one matched ELA-A molecule, but not of infected PBMC when tested on autologous target cells infected target cells from horses with a mismatch of both ELA-A with the control recombinant vaccinia virus (VSC11) exmolecules. The data in this paper suggest that the killing pressing b-galactosidase while the fifth (H-521) had 13 observed was MHC class I-restricted, but do not provide CTLm/10 6 PBMC when tested on this latter target cell direct proof. Previous work demonstrated that depleting (Table 2) . Furthermore, õ2 CTLm per 10 6 PBMC were CD8 / T lymphocytes removed EIAV-specific CTLe from detected in PBMC from the five carrier horses when ELA-PBMC from horses with recent EIAV infections (McGuire A-mismatched EK cells expressing either Env or Gag/Pr et al., 1994b) . Studies of EIAV-specific CTLm in PBMC were evaluated. In only one horse (H-521) did the sum from inapparent carriers using pokeweed mitogen-stimuof CTLm to Env and Gag/Pr proteins nearly equal the lated PBMC targets infected with recombinant vaccinia number of CTLm to EIAV-infected target cells. In the other viruses expressing EIAV proteins demonstrated both four carriers, this sum was less than the number reacting MHC class I-and MHC class II-restricted killing, although to EIAV-infected EK cells.
the MHC class I killing was greater (Hammond et al., 1997) . In addition, MHC class I restriction occurs with equine CTL killing of equine herpes virus I-infected target DISCUSSION cells (Allen et al., 1995) . The frequency of CTLm in PBMC from carrier horses The initial CTL assays in this study evaluated both PBMC stimulated in vitro with EIAV-infected autologous to EIAV-infected EK target cells ranged from 60 to 468 per 10 6 PBMC. These values are similar to some reported PBMC and nonstimulated PBMC. In vitro stimulation of PBMC from three carrier horses resulted in high levels for people infected with HIV-1 (Carmichael et al., 1993) , but are lower than those reported for a defined group of of specific lysis by CTLm. Similar results were obtained Health Service Grant AI-24291 from the National Institute of Allergy HIV-1-infected, long-term nonprogressors (Rinaldo et al., and Infectious Disease. 1995) . For comparison, the mean frequency of anti-EIAV CTLm in five carriers was 293 per 10 6 PBMC while anti-REFERENCES HIV-1 CTLm from seven long-term nonprogressor humans was approximately 1000 per 10 6 PBMC using tar-Allen, G., Yeargan, M., Costa, L., and Cross, R. (1995) . Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte re-gets infected with a vaccinia virus expressing Env, Gag, sponses in horses infected with herpesvirus I. J. Virol. 69, [606] [607] [608] [609] [610] [611] [612] and Pol proteins (Rinaldo et al., 1995) . The frequency of Bailey, E. (1980) . Identification and genetics of horse lymphocyte alloan-CTLm in PBMC from four carrier horses recognizing tartigens. Immunogenetics 11, 499-506.
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